GUANGDONG HYBRIBIO BIOTECH CO.,LTD. Financials Guangdong Hybribio Biotech Co.,Ltd.
Equities
300639
CNE100002N51
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.71 CNY | +0.15% |
|
+7.19% | -28.16% |
| 26/04 | Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 24/04 | Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,313 | 8,846 | 8,595 | 7,361 | 5,990 | 4,308 | - |
| Enterprise Value (EV) 1 | 5,313 | 8,846 | 8,595 | 7,361 | 5,990 | 4,308 | 4,308 |
| P/E ratio | 34.9 x | 23.2 x | 10.1 x | 4.29 x | 37.4 x | 15.3 x | 12 x |
| Yield | 0.82% | - | - | - | - | - | - |
| Capitalization / Revenue | 7.28 x | 6.53 x | - | 1.32 x | 5.42 x | 2.74 x | 2.08 x |
| EV / Revenue | 7.28 x | 6.53 x | - | 1.32 x | 5.42 x | 2.74 x | 2.08 x |
| EV / EBITDA | - | 1,66,04,338 x | - | - | - | - | - |
| EV / FCF | -6,63,43,233 x | - | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - | - |
| Price to Book | 4.91 x | 3.7 x | - | 1.51 x | 1.25 x | 0.86 x | 0.82 x |
| Nbr of stocks (in thousands) | 6,12,076 | 6,62,760 | 6,55,300 | 6,55,300 | 6,41,299 | 6,42,056 | - |
| Reference price 2 | 8.680 | 13.35 | 13.12 | 11.23 | 9.340 | 6.710 | 6.710 |
| Announcement Date | 19/02/20 | 01/04/21 | 25/03/22 | 14/04/23 | 23/04/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 729.4 | 1,355 | - | 5,597 | 1,104 | 1,575 | 2,074 |
| EBITDA | - | 532.7 | - | - | - | - | - |
| EBIT 1 | 156.3 | 458.6 | - | 2,193 | 42.6 | 353 | 452 |
| Operating Margin | 21.42% | 33.84% | - | 39.18% | 3.86% | 22.41% | 21.79% |
| Earnings before Tax (EBT) 1 | 154.5 | 453.8 | - | 2,128 | 36.82 | 353 | 452 |
| Net income 1 | 147.3 | 353.2 | 852.2 | 1,725 | 140.5 | 284 | 364 |
| Net margin | 20.19% | 26.06% | - | 30.83% | 12.72% | 18.03% | 17.55% |
| EPS 2 | 0.2486 | 0.5754 | 1.293 | 2.620 | 0.2500 | 0.4400 | 0.5600 |
| Free Cash Flow | -80.08 | - | - | - | - | - | - |
| FCF margin | -10.98% | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | 0.0710 | - | - | - | - | - | - |
| Announcement Date | 19/02/20 | 01/04/21 | 25/03/22 | 14/04/23 | 23/04/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -80.1 | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 14.5% | 20.7% | - | 42.4% | 2.88% | 5.3% | 6.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.770 | 3.610 | - | 7.440 | 7.490 | 7.810 | 8.230 |
| Cash Flow per Share 2 | - | 0.4700 | - | 1.990 | 0.4900 | 1.770 | 1.220 |
| Capex 1 | 193 | 280 | - | 721 | 368 | 530 | 505 |
| Capex / Sales | 26.45% | 20.67% | - | 12.88% | 33.28% | 33.65% | 24.35% |
| Announcement Date | 19/02/20 | 01/04/21 | 25/03/22 | 14/04/23 | 23/04/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.71
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.16% | 595M | |
| -1.34% | 12.58B | |
| -1.64% | 8.51B | |
| +0.09% | 5.29B | |
| +22.42% | 5.16B | |
| -0.09% | 4.55B | |
| -52.84% | 3.04B | |
| +20.02% | 3B | |
| +31.92% | 2.17B | |
| -2.45% | 1.92B |
- Stock Market
- Equities
- 300639 Stock
- Financials Guangdong Hybribio Biotech Co.,Ltd.